- An asymmetric synthesis of a chiral sulfone acid with concomitant hydrolysis and oxidation to enable the preparation of a glucokinase activator
-
This contribution describes the demonstration of an asymmetric synthesis of a glucokinase activator via protonation of the enolate generated from an alkylaryl ketene and (R)-pantolactone. Additionally, a one-pot hydrolysis/oxidation protocol with lithium hydroperoxide was developed to afford a chiral sulfone acid without degradation of the labile stereocenter.
- DeBaillie, Amy C.,Magnus, Nicholas A.,Laurila, Michael E.,Wepsiec, James P.,Ruble, J. Craig,Petkus, Jeffrey J.,Vaid, Radhe K.,Niemeier, Jeffry K.,Mick, Joseph F.,Gunter, Thomas Z.
-
p. 1538 - 1543
(2013/02/23)
-
- Highly enantioselective hydrogenation of α-aryl-β-substituted acrylic acids catalyzed by Ir-SpinPHOX
-
The enantioselective hydrogenation of a series of challenging substrates, α-aryl-β-substituted acrylic acids, was realized with high efficiency and enantioselectivity (up to 96%) under the catalysis of Ir(i) complex of Spiro-based P,N ligand, SpinPHOX.
- Zhang, Yi,Han, Zhaobin,Li, Fuying,Ding, Kuiling,Zhang, Ao
-
supporting information; experimental part
p. 156 - 158
(2010/04/02)
-
- NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
-
Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; R1 is aryl or heteroaryl; R2 is halogen, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R5 is as defined herein; Z is O, S, S(O), S(O)2, or NR5a; X is S, O, N, NR3, or CR3; Y is NCR4 or N4; R3, R4, and R5 are as defined herein; R8 is aryl or heteroaryl; R6 and R7 are independently H, halogen, or alkyl; m is 0 or 1; and n is 0 to 3, or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.
- -
-
Page/Page column 34
(2008/06/13)
-
- NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
-
Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n-Z-(CH2)m—PO(OR7)(OR8), —(CH2)nZ-(CH2)m—PO(OR7)Rg, —(CH2)n-Z-(CH2)m—OPO(OR7)Rg, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10);R5 and R6 are independently selected from H, alkyl and halogen;Y is R7(CH2)s or is absent; andX, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.
- -
-
Page/Page column 65
(2008/06/13)
-